Kezar Life Sciences Announces Pricing of Initial Public Offering
South San Francisco, CA, June 20, 2018 – Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, announced today that it has priced its initial public offering of 5,000,000 shares of its common stock at a public offering price of $15.00 per share. The gross proceeds to Kezar, before deducting underwriting discounts, commissions and offering expenses, is expected to be approximately $75 million. All of the common stock is being offered by Kezar. In addition, Kezar has granted the underwriters a 30-day option to purchase up to 750,000 additional shares of common stock to cover over-allotments, if any, at the initial public offering price, less the underwriting discounts and commissions. The common stock are expected to begin trading on The Nasdaq Global Select Market on June 21, 2018 under the trading symbol “KZR.” The offering is expected to close on June 25, 2018, subject to customary closing conditions.
© 2018 Pappas Capital, LLC. ALL RIGHTS RESERVED.